Periodontal Regeneration With Hyaluronic Acid or Enamel Matrix Derivatives
Study Details
Study Description
Brief Summary
To date, the quest for ideal biological inductors for periodontal regeneration is still ongoing, especially when facing non-containing defect anatomies. The primary aim of this study is to evaluate the clinical and radiographic performance of a bone graft combined with either enamel matrix derivatives or hyaluronic acid for periodontal regeneration of non-containing intrabony defects in terms of clinical attachment gain (primary outcome) and other secondary outcomes (probing pocket depth reduction, radiographic bone fill). Moreover, this study aims to compare early wound healing and patient-reported outcome measures.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Hyaluronic acid Minimally invasive surgical technique with a combined approach using hyaluronic acid gel and a bone xenograft. |
Device: Hyaluronic acid
Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
|
| Active Comparator: Enamel matrix derivatives Minimally invasive surgical technique with a combined approach using enamel matrix derivatives gel and a bone xenograft. |
Device: Enamel matrix derivatives
Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
|
Outcome Measures
Primary Outcome Measures
- Clinical attachment level change [24 months]
Clinical attachment level will be assessed on the experimental teeth using periodontal probe (PCP 15/11.5, Hu-Friedy, Chicago, IL, USA)
Secondary Outcome Measures
- Probing pocket depth change [24 months]
Probing depth will be assessed on the experimental teeth using periodontal probe (PCP 15/11.5, Hu-Friedy, Chicago, IL, USA)
- Radiographic bone level change [24 months]
Periapical standardized radiographs will be taken by a clinician masked to the clinical measurements using the paralleling technique and individually customized bite-blocks (RINN XCP Film Holding Instruments, Dentsply, York, USA)
- Patient reported outcome measures [14 weeks]
Pain will be self-recorded by the patient using a visual analog scale (from 0 to 10)
Eligibility Criteria
Criteria
Inclusion criteria:
-
Diagnosis of stage III-IV periodontitis.
-
Completed steps I-II periodontal therapy.
-
FMPS <15% at 3-month re-evaluation.
-
FMBS <15% at 3-month re-evaluation.
-
At least one site with intrabony defects and residual PPD ≥ 6 mm at re-evaluation, with a radiographic intrabony component ≥ 3 mm, and limited to no extension of the defect on the lingual or palatal side as assessed by preoperative bone sounding.
-
Intrasurgically, the defect has to present a non-supporting anatomy (1-2 residual walls in its most coronal portion) and it needs to be accessible by flap elevation only on one side (either buccal or oral).
-
Signed informed consent.
Exclusion criteria:
-
Compromised general health which contraindicates the study procedures (ASA III-VI patients).
-
Systemic diseases/medications which could influence the outcome of the therapy (e.g. uncontrolled diabetes mellitus, non-plaque-induced gingival diseases, antiepileptic drugs (phenytoin and sodium valproate), certain calcium channel-blocking drugs (e.g., nifedipine, verapamil, diltiazem, amlodipine, felodipine), immunoregulating drugs (e.g., ciclosporine), and high-dose oral contraceptives).
-
Current smokers (self-reported, ≥ 10 cigarettes a day), users of chewing tobacco, and drug/alcohol abusers.
-
Pregnant or nursing women.
-
Presence of furcation involvement ≥ II degree (Hamp 1975) at the affected teeth.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CIR Dental School | Turin | Italy | 10126 |
Sponsors and Collaborators
- University of Turin, Italy
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HATurin